Global Pregabalin Market Size study, By Dosage Forms (Oral Capsule, Oral Solution, Oral Tablet, Extended Release), By Application (Epilepsy, Neuropathic Pain, Anxiety Disorder, Others), By Drug Class (Fibromyalgia Agents, Anticonvulsants, Others), By End-

Global Pregabalin Market Size study, By Dosage Forms (Oral Capsule, Oral Solution, Oral Tablet, Extended Release), By Application (Epilepsy, Neuropathic Pain, Anxiety Disorder, Others), By Drug Class (Fibromyalgia Agents, Anticonvulsants, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028

Global Pregabalin Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Pregabalin also called an anticonvulsant is an anti-epileptic medication, used for treatment of neurological conditions such as epilepsy and anxiety. It is also effective in treatment of nerve pain, such as burning, shooting, or stabbing pain. Pregabalin comes in capsules and oral solution. Rising prevalence of epilepsy worldwide and increasing application of Lyrica (Pregabalin) as well as growing healthcare expenditure are driving the growth for Pregabalin Market. For instance, according to World Health Organization (WHO) – as of 2021, around 5 million people are diagnosed with epilepsy every year. This disease is more prevalent in Low- & Middle-income countries. In low-income countries 139 per 100 000 people are affected by epilepsy. Whereas, in high income countries 49 per 100 000 people diagnosed with epilepsy each year . Moreover, in August 20219, The United States Food and Drug Administration granted approvals to nine pharma companies for development of first generic version of Lyrica (pregabalin). These nine companies were Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories, Rising Pharmaceuticals, Sciegen Pharmaceuticals, and Teva Pharmaceuticals. Also, growing number of generic drug manufacturers and rising healthcare sector in emerging markets are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, side effects associated with Pregabalin impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Pregabalin Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to presence of leading market players and favorable government initiatives towards generic drug manufacturing in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as increasing prevalence of neurological disorders and growing healthcare infrastructure in the region, would create lucrative growth prospects for the Pregabalin Market across the Asia Pacific region.

Major market players included in this report are:
Pfizer Inc. (US)
GlaxoSmithKline plc (UK)
Novartis AG (Switzerland)
Mylan N.V. (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
F. Hoffmann-La Roche Ltd. (Switzerland)
Aurobindo Pharma (India)
Lupin (India)
Zydus Cadila (India)


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Dosage Forms
Oral Capsule
Oral Solution
Oral Tablet
Extended Release
By Application
Epilepsy
Neuropathic Pain
Anxiety Disorder
Others
By Drug Class
Fibromyalgia Agents
Anticonvulsants
Others
By End-Users
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Pregabalin Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Pfizer Inc. (US)
GlaxoSmithKline plc (UK)
Novartis AG (Switzerland)
Mylan N.V. (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
F. Hoffmann-La Roche Ltd. (Switzerland)
Aurobindo Pharma (India)
Lupin (India)
Zydus Cadila (India)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.